Semaglutide cuts risk of major CV events

Trial results

• The double-blinded SELECT trial compared SC once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for preventing major adverse cardiovascular events (MACEs) over a period of up to five years.
• The trial enrolled 17,604 adults ages 45 years or older who are overweight or obese, with established CVD, and no history of diabetes.
• The primary objective was reached by demonstrating a statistically significant and superior reduction in MACE of 20% among individuals treated with semaglutide 2.4 mg vs. placebo.
• Semaglutide 2.4 mg appeared to be safe and well-tolerated, in line with previous trials.

Source:

(2023, August 8). Novo Nordisk. Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html